Biogen tosses in an extra $50M for a bigger slice of the royalties for its PhIII Alzheimer’s drug aducanumab
Biogen $BIIB is once again signaling its confidence in the late-stage success of its high-risk Alzheimer’s drug aducanumab this morning, handing out $50 million to its partners at Neurimmune in exchange for a 5% cut in the royalty rates it will be due in the event the drug hits the market.
If they’re right, Biogen’s deal was a steal. And if they’re wrong, no one is likely to grouse about an extra $50 million loss against the backdrop of an epic fail taking down the one late-stage Alzheimer’s drug that can still muster enthusiasm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.